Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1982 1
1984 2
1985 3
1986 1
1987 1
1988 2
1989 4
1990 3
1991 2
1992 2
1993 4
1994 5
1995 3
1996 3
1997 8
1998 3
1999 9
2000 4
2001 3
2002 6
2003 7
2004 6
2005 4
2006 4
2007 8
2008 6
2009 7
2010 16
2011 13
2012 14
2013 9
2014 8
2015 7
2016 12
2017 10
2018 14
2019 7
2020 8
2021 4
2022 2
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Results by year

Filters applied: . Clear all
Page 1
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions.
Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, Bunn PA Jr, Renyi-Vamos F, Schelch K, Prosch H, Byers LA, Hirsch FR, Dome B. Megyesfalvi Z, et al. Among authors: pirker r. CA Cancer J Clin. 2023 Nov-Dec;73(6):620-652. doi: 10.3322/caac.21785. Epub 2023 Jun 17. CA Cancer J Clin. 2023. PMID: 37329269 Free article. Review.
Lung Cancer in Austria.
Pirker R, Prosch H, Popper H, Klepetko W, Dieckmann K, Burghuber OC, Klikovits T, Hoda MA, Zöchbauer-Müller S, Filipits M. Pirker R, et al. J Thorac Oncol. 2021 May;16(5):725-733. doi: 10.1016/j.jtho.2020.10.158. J Thorac Oncol. 2021. PMID: 33896572 Free article. No abstract available.
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Han B, et al. Among authors: pirker r. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. doi: 10.1001/jamaoncol.2018.3039. JAMA Oncol. 2018. PMID: 30098152 Free PMC article. Clinical Trial.
Scientific Advances in Lung Cancer 2015.
Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Tsao AS, et al. Among authors: pirker r. J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. J Thorac Oncol. 2016. PMID: 27013409 Free article. Review.
Cetuximab in non-small-cell lung cancer.
Pirker R, Filipits M. Pirker R, et al. Transl Lung Cancer Res. 2012 Mar;1(1):54-60. doi: 10.3978/j.issn.2218-6751.11.01. Transl Lung Cancer Res. 2012. PMID: 25806155 Free PMC article. Review.
Erythropoietin in cancer: an update.
Tóvári J, Pirker R, Tímár J, Ostoros G, Kovács G, Döme B. Tóvári J, et al. Among authors: pirker r. Curr Mol Med. 2008 Sep;8(6):481-91. doi: 10.2174/156652408785747979. Curr Mol Med. 2008. PMID: 18781955 Review.
219 results